Standard Biotools Inc. (LAB): who owns it and who trades it
As of Nov 16, 2026, LAB insiders reported 10 purchases worth $12.2M in the last 12 months. The largest buyer was Casdin Partners GP, LLC (Director), with $10M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Standard Biotools
From the latest filingsOverall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LAB
144 funds and institutions reported LAB shares worth $245M at the end of Q2 2026, about 76% of the company. The largest holder is Casdin Capital, LLC with 22.8%.
Funds and institutions (13F) 76%Everyone else 24%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Casdin Capital, LLC | 88.78M | 22.76% | $73M | No change |
| Viking Global Investors LP | 58.65M | 15.04% | $48.3M | No change |
| Mak Capital One LLC | 28.81M | 7.39% | $23.7M | +10% |
| Long Focus Capital Management, LLC | 23.50M | 6.02% | $19.3M | +47% |
| Vanguard Capital Management LLC | 12.25M | 3.14% | $10.1M | -4% |
| BlackRock, Inc. | 8.25M | 2.12% | $6.8M | -67% |
| Hollow Brook Wealth Management LLC | 5.50M | 1.41% | $4.5M | -3% |
| Neuberger Berman Group LLC | 4.96M | 1.27% | $4M | +6% |
| Qube Research & Technologies Ltd | 4.82M | 1.24% | $4M | +584% |
| Royce & Associates LP | 4.53M | 1.16% | $3.7M | +51% |
| Geode Capital Management, LLC | 3.90M | 1.00% | $3.2M | -47% |
| Tikvah Management LLC | 3.55M | 0.91% | $2.9M | No change |
| Millennium Management LLC | 3.51M | 0.90% | $2.9M | +67% |
| Morgan Stanley | 2.83M | 0.73% | $2.3M | -2% |
| D. E. Shaw & Co., Inc. | 2.82M | 0.72% | $2.3M | +1315% |
| Jane Street Group, LLC | 2.51M | 0.64% | $2.1M | – |
| Peapod Lane Capital LLC | 2.41M | 0.62% | $2M | +19% |
| Citadel Advisors LLC | 2.35M | 0.60% | $1.9M | +92% |
| Mink Brook Asset Management LLC | 2.19M | 0.56% | $1.8M | – |
| Sone Capital Management, LLC | 2.13M | 0.55% | $1.8M | +21% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LAB insiders reported $12.2M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Thomas D. Carey | Director | Purchase | 75,000 | $0.63 | $46.9K | Form 4 |
| Dec 4, 2025 | Casdin Private Growth Equity Fund Gp, Llc +7 | Director | Purchase | 150,000 | $1.45 | $218K | Form 4 |
| Dec 3, 2025 | Casdin Private Growth Equity Fund Gp, Llc +7 | Director | Purchase | 75,000 | $1.44 | $108K | Form 4 |
| Dec 2, 2025 | Casdin Private Growth Equity Fund Gp, Llc +7 | Director | Purchase | 125,000 | $1.42 | $178K | Form 4 |
| Nov 25, 2025 | Casdin Partners GP, LLC +7 | Director | Purchase | 7.55M | $1.30 | $9.8M | Form 4 |
| Nov 24, 2025 | Casdin Partners GP, LLC +7 | Director | Purchase | 150,000 | $1.43 | $214K | Form 4 |
| Nov 20, 2025 | Eli Casdin +7 | Director | Purchase | 450,000 | $1.30 | $585K | Form 4 |
| Nov 19, 2025 | Eli Casdin +7 | Director | Purchase | 350,000 | $1.28 | $448K | Form 4 |
| Nov 18, 2025 | Eli Casdin +7 | Director | Purchase | 275,000 | $1.23 | $338K | Form 4 |
| Nov 17, 2025 | Casdin Partners Master Fund, L.P. +7 | Director | Purchase | 225,000 | $1.22 | $274K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Casdin Partners GP, LLC | Director, 10% owner | $10M | – | Nov 25, 2025 |
| Eli Casdin | Director, 10% owner | $1.4M | – | Nov 20, 2025 |
| Casdin Private Growth Equity Fund Gp, Llc | Director | $503K | – | Dec 4, 2025 |
| Casdin Partners Master Fund, L.P. | Director, 10% owner | $274K | – | Nov 17, 2025 |
| Thomas D. Carey | Director | $46.9K | – | Nov 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LAB short interest
Low short interest. 0.6% of LAB shares are sold short: about 1 share in 181. Over the last 12 reports the number of shares short went down 83%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.17M LAB shares were sold short, 0.6% of the shares outstanding, down 11.3% from the report before. At the average daily volume of 706,767 shares, buying them all back would take about 3.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.17M | 0.55% | -11% | 706,767 | 3.1 |
| Oct 15, 2026 | 2.45M | 0.62% | -3% | 979,906 | 2.5 |
| Sep 30, 2026 | 2.52M | 0.64% | -3% | 925,491 | 2.7 |
| Sep 15, 2026 | 2.59M | 0.66% | -13% | 1.80M | 1.4 |
| Aug 31, 2026 | 2.98M | 0.76% | +24% | 1.70M | 1.8 |
| Aug 14, 2026 | 2.41M | 0.61% | -11% | 1.11M | 2.2 |
| Jul 31, 2026 | 2.69M | 0.69% | +22% | 2.02M | 1.3 |
| Jul 15, 2026 | 2.21M | 0.57% | -35% | 3.06M | 1.0 |
| Jun 30, 2026 | 3.43M | 0.88% | -66% | 6.85M | 1.0 |
| Jun 15, 2026 | 10.03M | 2.57% | -24% | 4.95M | 2.0 |
| May 29, 2026 | 13.13M | 3.37% | +2% | 2.22M | 5.9 |
| May 15, 2026 | 12.92M | 3.31% | +9% | 1.85M | 7.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Standard Biotools company events
Standard Biotools filed 16 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership, control, listing). The latest was on Nov 3, 2026.
- Nov 3, 2026AnnouncementShared information with investors. Filing
- Oct 5, 2026AnnouncementShared information with investors. Filing
- Sep 30, 2026AgreementAs previously disclosed, on July 28, 2026, Standard BioTools Inc., a Delaware corporation, entered into a Share and Asset Purchase Agreement with Multiplex Bio Inc., a Delaware corporation, pursuant to which Multiplex Bio agreed to acquire the mass cytometry business of the Company. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 28, 2026AgreementStandard BioTools Inc., a Delaware corporation, entered into a Termination, Waiver and Release Agreement with Illumina, Inc., a Delaware corporation. Filing
- Jul 24, 2026ListingStandard BioTools Inc. (NASDAQ: LAB) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company did not meet the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on The Nasdaq Global… Filing
- Jun 18, 2026LeadershipStandard BioTools Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026. Filing
- Jun 8, 2026ControlTo the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
- Jun 5, 2026AnnouncementStandard BioTools Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that it has regained compliance with Nasdaq Listing Rule 5450(a)(1). Filing
- Jun 3, 2026LeadershipThe Human Capital Committee of the Board of Directors of Standard BioTools Inc. approved a grant of 500,000 restricted stock units for Sean Mackay, Chief Business Officer of the Company, under the Company’s 2026 Equity Incentive Plan, effective as of June 20, 2026. Filing
- May 28, 2026LeadershipThe Board of Directors of Standard BioTools Inc. approved the Company’s 2026 Change of Control and Severance Plan and Participation Agreement thereunder. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 24, 2026ListingStandard BioTools Inc. (NASDAQ: LAB) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company did not meet the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on The Nasdaq Global… Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Jan 30, 2026DealStandard BioTools Inc., a Delaware corporation completed the previously announced sale of all of the equity interests of SomaLogic, Inc., Sengenics Corporation LLC and Sengenics Corporation Pte Ltd (such equity interests, collectively, the “ Shares ”), the entities that operate the Company’s… Filing
- Jan 8, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Standard Biotools financials
Famous investors that hold LAB
5 of the 50 well-known investors we track reported holding LAB in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $43.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 58.65M | $43.4M | 0.1% | No change |
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.57M | $1.9M | 0.0% | +9% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.04M | $1.5M | 0.0% | +106% |
| Israel Englander · Millennium Management | Q3 2026 | 532,466 | $394K | 0.0% | -85% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 104,678 | $77.5K | 0.0% | -85% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named LAB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | MAK Capital Fund LP | 13G/A | 6.3% |
| Nov 16, 2026 | MAK Capital Fund LP | 13G/A | 6.3% |
Questions about Standard Biotools Inc. (LAB) stock
Who owns the most LAB stock?
The largest reported owner of Standard Biotools Inc. (LAB) is Casdin Capital, LLC, with 22.8% of the company. In total, 144 funds and institutions reported holding LAB at the end of Q2 2026, together about 76% of the shares. See the largest owners.
Are LAB insiders buying or selling?
In the last 12 months, LAB insiders reported 10 open-market purchases worth $12.2M and no sales. The latest trade was on Nov 5, 2026. See every trade.
What is the short interest in LAB?
As of Oct 30, 2026, 2.17M LAB shares were sold short, 0.6% of the shares outstanding, down 11.3% from the report before. At the average daily volume of 706,767 shares, buying them all back would take about 3.1 trading days (days to cover). See the history.
Which famous investors hold LAB?
5 of the 50 well-known investors we track reported LAB in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Jim Simons. The largest position is worth $43.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.